Education
About Us
Working with TipRanks
Follow Us
Biogen (BIIB)
NASDAQ:BIIB
BIIB Stock Chart & Stats
$191.20
-$1.36(-0.89%)
At close: 4:00 PM EST
$191.20
-$1.36(-0.89%)
Day’s Range― - ―
52-Week Range$110.04 - $202.41
Previous CloseN/A
Volume268.56K
Average Volume (3M)1.52M
Market Cap
$28.06B
Enterprise Value$32.78B
Total Cash (Recent Filing)$3.82B
Total Debt (Recent Filing)$6.95B
Price to Earnings (P/E)21.7
Beta0.66
Next Earnings
May 06, 2026EPS Estimate
3.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.99
Shares Outstanding146,758,530
10 Day Avg. Volume1,768,975
30 Day Avg. Volume1,520,632
Financial Highlights & Ratios
PEG Ratio-0.95
Price to Book (P/B)1.41
Price to Sales (P/S)2.63
P/FCF Ratio12.59
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue3.34
Enterprise Value/Gross Profit4.74
Enterprise Value/Ebitda10.57
Forecast
1Y Price Target
$206.23Price Target Upside7.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering26
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial Performance And ValuationStronger-than-expected quarterly performance and contributions from new product launches are improving profitability and support analyst views that the stock may be undervalued versus major biopharma peers.
Pipeline Clinical CatalystsMultiple late-stage clinical programs, including a tau antisense oligonucleotide and a Phase III lupus antibody, present registrational readouts that could materially re-rate the stock if results are positive.
Treatment AccessibilityAvailability of a subcutaneous autoinjector for Leqembi eases administration and supports higher patient continuation, which could expand the treated population.
Bears Say
Commercialization PaceManagement guidance that rapid sales growth after subcutaneous approval is unlikely implies commercialization is likely to unfold gradually, delaying revenue inflection points.
Legacy Franchise DeclineErosion of the multiple sclerosis product portfolio is reducing overall revenue and may offset gains from newer products.
Regulatory And Statistical RiskThe secondary kidney function endpoint for felzartamab carries substantial statistical risk and could limit the therapy's approval scope and commercial adoption.
Biogen News
BIIB FAQ
What was Biogen’s price range in the past 12 months?
Biogen lowest stock price was $110.03 and its highest was $202.41 in the past 12 months.
What is Biogen’s market cap?
Biogen’s market cap is $28.06B.
When is Biogen’s upcoming earnings report date?
Biogen’s upcoming earnings report date is May 06, 2026 which is in 80 days.
How were Biogen’s earnings last quarter?
Biogen released its earnings results on Feb 06, 2026. The company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.625 by $0.365.
Is Biogen overvalued?
According to Wall Street analysts Biogen’s price is currently Undervalued.
Does Biogen pay dividends?
Biogen does not currently pay dividends.
What is Biogen’s EPS estimate?
Biogen’s EPS estimate is 3.07.
How many shares outstanding does Biogen have?
Biogen has 146,758,530 shares outstanding.
What happened to Biogen’s price movement after its last earnings report?
Biogen reported an EPS of $1.99 in its last earnings report, beating expectations of $1.625. Following the earnings report the stock price went up 8.535%.
Which hedge fund is a major shareholder of Biogen?
Currently, no hedge funds are holding shares in BIIB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biogen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$206.23 (7.86% Upside)
$206.23 (7.86% Upside)
Blogger Sentiment
Bullish
BIIB Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 725.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $665.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Very Bullish
Bullish news 96%
Bearish news 4%
Bearish news 4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.16%
12-Months-Change
Fundamentals
Return on Equity
7.39%
Trailing 12-Months
Asset Growth
4.96%
Trailing 12-Months
Company Description
Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
BIIB Company Deck
BIIB Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed balanced optimism: Biogen reported strong operating cash flow, solid EPS, a growing cohort of recently launched 'growth' products and meaningful pipeline and regulatory progress (priority review, breakthrough designation, new INDs and acquisition activity). These positives are tempered by near‑term revenue guidance calling for a mid‑single‑digit decline in 2026, ongoing competitive pressures on legacy MS products (generics and biosimilars), one‑time charges that weighed on GAAP results and reimbursement/inventory timing uncertainties that could dampen near‑term revenue trajectories. The company is investing for launches and pipeline progression while managing legacy declines.View all BIIB earnings summariesBIIB Revenue Breakdown
71.98% Product revenue
18.81% Revenue from anti-CD20 therapeutic programs
1.80% Alzheimer's collaboration revenue
7.41% Contract manufacturing, royalty and other revenue
BIIB Stock 12 Month Forecast
Average Price Target
$206.23
▲(7.86% Upside)
Technical Analysis
Ownership Overview
0.18% Insiders
30.72% Mutual Funds
0.20% Other Institutional Investors
40.84% Public Companies and Individual Investors